NO20032395D0 - Ekspresjonsanalyse av FKBP-nukleinsyrer og polypeptider anvendelige i diagnose og behandling av prostatakreft - Google Patents

Ekspresjonsanalyse av FKBP-nukleinsyrer og polypeptider anvendelige i diagnose og behandling av prostatakreft

Info

Publication number
NO20032395D0
NO20032395D0 NO20032395A NO20032395A NO20032395D0 NO 20032395 D0 NO20032395 D0 NO 20032395D0 NO 20032395 A NO20032395 A NO 20032395A NO 20032395 A NO20032395 A NO 20032395A NO 20032395 D0 NO20032395 D0 NO 20032395D0
Authority
NO
Norway
Prior art keywords
diagnosis
treatment
nucleic acids
prostate cancer
expression analysis
Prior art date
Application number
NO20032395A
Other languages
English (en)
Other versions
NO20032395L (no
Inventor
Kimberly A Gillis
Yixian Zhang
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20032395D0 publication Critical patent/NO20032395D0/no
Publication of NO20032395L publication Critical patent/NO20032395L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9493—Immunosupressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/50—Detection characterised by immobilisation to a surface
    • C12Q2565/501—Detection characterised by immobilisation to a surface being an array of oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20032395A 2000-11-28 2003-05-27 Ekspresjonsanalyse av FKBP-nukleinsyrer og polypeptider anvendelige i diagnose og behandling av prostatakreft NO20032395L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25353900P 2000-11-28 2000-11-28
PCT/US2001/044536 WO2002044418A2 (en) 2000-11-28 2001-11-28 Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer

Publications (2)

Publication Number Publication Date
NO20032395D0 true NO20032395D0 (no) 2003-05-27
NO20032395L NO20032395L (no) 2003-07-14

Family

ID=22960688

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032395A NO20032395L (no) 2000-11-28 2003-05-27 Ekspresjonsanalyse av FKBP-nukleinsyrer og polypeptider anvendelige i diagnose og behandling av prostatakreft

Country Status (14)

Country Link
US (3) US6821731B2 (no)
EP (2) EP1356108A2 (no)
JP (4) JP2004526425A (no)
AU (1) AU2002241524A1 (no)
BR (1) BR0115715A (no)
CA (1) CA2429722A1 (no)
HU (1) HUP0303888A3 (no)
IL (1) IL155952A0 (no)
MX (1) MXPA03004688A (no)
NO (1) NO20032395L (no)
NZ (1) NZ526708A (no)
PL (1) PL365605A1 (no)
WO (1) WO2002044418A2 (no)
ZA (1) ZA200304996B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE427948T1 (de) * 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
US7745180B2 (en) * 2002-04-24 2010-06-29 Hitachi Chemical Co., Ltd. Device and method for high-throughput quantification of mRNA from whole blood
US7655397B2 (en) * 2002-04-25 2010-02-02 The United States Of America As Represented By The Department Of Health And Human Services Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers
US7774143B2 (en) * 2002-04-25 2010-08-10 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for analyzing high dimensional data for classifying, diagnosing, prognosticating, and/or predicting diseases and other biological states
CA2484640C (en) * 2002-05-15 2012-01-17 Endocyte, Inc. Vitamin-mitomycin conjugates
US20050042621A1 (en) * 2002-09-27 2005-02-24 Affymetrix, Inc. Method for preparing a nucleic acid sample for hybridization to an array
WO2004069159A2 (en) 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
JP5289935B2 (ja) 2005-03-16 2013-09-11 エンドサイト，インコーポレイテッド プテロイン酸およびその結合体の合成と精製
US20080280937A1 (en) * 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
ES2468240T3 (es) 2005-08-19 2014-06-16 Endocyte, Inc. Conjugados de ligando de múltiples fármacos
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN101678124A (zh) * 2007-03-14 2010-03-24 恩多塞特公司 结合配体连接的微管溶素递药缀合物
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
EP3569251A1 (en) 2007-06-25 2019-11-20 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
CA2703491C (en) 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
US11179361B2 (en) 2008-08-08 2021-11-23 City Of Hope Methods of quantifying N2-(1-carboxyethyl)-2′-deoxy-guanosine (CEdG) and synthesis of oligonucleotides containing CEdG
US20100102218A1 (en) * 2008-08-08 2010-04-29 Samuel Rahbar METHODS OF QUANTIFYING N2-(1-CARBOXYETHYL)-2'-DEOXY-GUANOSINE (CEdG) AND SYNTHESIS OF OLIGONUCLEOTIDES CONTAINING CEdG
CN102549438B (zh) * 2009-09-24 2014-10-29 国家健康与医学研究院 Fkbp52-tau相互作用作为新颖治疗靶点用于治疗涉及tau机能失调的神经障碍
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
AU2013331440A1 (en) 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
GB201322034D0 (en) 2013-12-12 2014-01-29 Almac Diagnostics Ltd Prostate cancer classification
US10155935B2 (en) * 2014-03-12 2018-12-18 Novozymes A/S Polypeptides with lipase activity and polynucleotides encoding same
JP6755264B2 (ja) 2015-05-18 2020-09-16 コーセプト セラピューティクス， インコーポレイテッド クッシング症候群についての処置を診断および評価するための方法
WO2019152728A1 (en) 2018-02-02 2019-08-08 City Of Hope Methods of quantifying methylglyoxal-induced nucleic acid adducts

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5030559A (en) 1986-04-01 1991-07-09 Board Of Regents, The University Of Texas System Methods and compositions for the identification of metastatic human tumors
DE122007000007I1 (de) 1986-04-09 2007-05-16 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5118611A (en) 1988-07-25 1992-06-02 Adeza Biomedical Corporation Adenocarcinoma antigen binding methods and reagents
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990002809A1 (en) 1988-09-02 1990-03-22 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5459039A (en) 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
EP0437576B1 (en) 1989-07-25 2002-07-03 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
US5393788A (en) 1990-07-10 1995-02-28 Smithkline Beecham Corporation Phenylalkyl oxamides
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5605930A (en) 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5428011A (en) 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
US5674682A (en) 1992-10-29 1997-10-07 Thomas Jefferson University Nucleic acid primers for detecting micrometastasis of prostate cancer
CA2153387A1 (en) 1993-01-07 1994-07-21 Hubert Koester Dna sequencing by mass spectrometry
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
US5723302A (en) 1993-05-14 1998-03-03 Nordion International Inc. Detection of prostate-specific antigen in breast tumors
GB9309966D0 (en) 1993-05-14 1993-06-30 Nordion Int Inc Detection of prostrate-specific antigen in breast tumors
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
CN1046944C (zh) 1993-12-17 1999-12-01 山道士有限公司 雷怕霉素类衍生物
IL112873A (en) 1994-03-08 2005-03-20 Wyeth Corp Rapamycin-fkbp12 binding proteins, their isolation and their use
WO1995028498A1 (en) 1994-04-15 1995-10-26 The Trustees Of Columbia University In The City Of New York Method for molecular staging of prostate cancer
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5856112A (en) 1994-06-16 1999-01-05 Urocor, Inc. Method for selectively inducing biomarker expression in urologic tumor tissue for diagnosis and treatment thereof
US5635197A (en) 1995-03-21 1997-06-03 Eli Lilly And Company Treatment and prevention of prostatic cancer metastasis
US5629007A (en) 1995-03-21 1997-05-13 Eli Lilly And Company Method of preventing prostatic cancer development
US5633161A (en) 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
US5968802A (en) 1995-06-07 1999-10-19 Wang; Bruce Nuclear cyclophilin
US5859031A (en) 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
RU2158267C2 (ru) 1995-06-09 2000-10-27 Новартис Аг Производные рапамицина и фармацевтическая композиция на их основе
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US5854206A (en) 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5801197A (en) 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5905027A (en) 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
AU728186B2 (en) 1996-03-15 2001-01-04 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
US5861248A (en) 1996-03-29 1999-01-19 Urocor, Inc. Biomarkers for detection of prostate cancer
US5976838A (en) 1996-12-18 1999-11-02 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
WO1998037418A2 (en) 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
NZ337446A (en) 1997-02-25 2001-02-23 Corixa Corp Immunogenic portions of a prostate protein and their use in immunotherapy of prostate cancer and methods for their use
EP0974652A4 (en) 1997-04-08 2000-08-30 Banyu Pharma Co Ltd GENE ASSOCIATED WITH CANCER METASTASE
AU9689398A (en) 1997-10-07 1999-04-27 Corixa Corporation Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer
WO1999022773A2 (en) 1997-11-05 1999-05-14 Baylor College Of Medicine Sequences for targeting metastatic cells
US5945522A (en) 1997-12-22 1999-08-31 Genset Prostate cancer gene
US5972615A (en) 1998-01-21 1999-10-26 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
WO1999037811A1 (en) 1998-01-21 1999-07-29 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
EP0939084A1 (en) 1998-02-11 1999-09-01 Ramanath B. Rao An estrogen binding proteinaceous substance, its possible role in estrogen action, and potential use.
KR20010083111A (ko) 1998-07-14 2001-08-31 길리스 스티브 전립선암의 치료 및 진단을 위한 조성물 및 방법
GB9815696D0 (en) 1998-07-20 1998-09-16 Pfizer Ltd Heterocyclics
AU5815699A (en) 1998-09-08 2000-03-27 Urocor, Inc. Prostate specific promoter and regulation of gene expression
US6251932B1 (en) 1998-09-25 2001-06-26 Asta Medica Ag Immunophilin ligands
JP2002531061A (ja) 1998-09-30 2002-09-24 ミレニアム ファーマシューティカルズ インク． 前立腺癌の診断および治療において有用な特異的核酸およびポリペプチドの発現解析
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
AU2002214576A1 (en) * 2000-10-13 2002-04-22 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genes related to development of refractory prostate cancer
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Also Published As

Publication number Publication date
US7402388B2 (en) 2008-07-22
PL365605A1 (en) 2005-01-10
MXPA03004688A (es) 2003-09-05
NO20032395L (no) 2003-07-14
JP2009242417A (ja) 2009-10-22
US20050069946A1 (en) 2005-03-31
US6821731B2 (en) 2004-11-23
NZ526708A (en) 2005-07-29
JP2011043496A (ja) 2011-03-03
EP2316976A1 (en) 2011-05-04
HUP0303888A3 (en) 2007-05-02
WO2002044418A3 (en) 2003-08-21
AU2002241524A1 (en) 2002-06-11
JP2004526425A (ja) 2004-09-02
US20020168650A1 (en) 2002-11-14
JP2008271979A (ja) 2008-11-13
BR0115715A (pt) 2004-02-03
HUP0303888A2 (hu) 2004-03-01
WO2002044418A2 (en) 2002-06-06
ZA200304996B (en) 2004-09-27
IL155952A0 (en) 2003-12-23
CA2429722A1 (en) 2002-06-06
EP1356108A2 (en) 2003-10-29
US20090062133A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
NO20032395D0 (no) Ekspresjonsanalyse av FKBP-nukleinsyrer og polypeptider anvendelige i diagnose og behandling av prostatakreft
NO20023402D0 (no) Blandinger og fremgangsmåter for behandling og diagnose av prostatakreft
NO20013002D0 (no) Blandinger og fremgangsmåter for behandling og diagnose av ovariekreft
NO20010196D0 (no) Sammensetninger og fremgangsmåter for terapi og diagnose av prostatakreft
FI990559A0 (fi) Näytteenkäsittelymenetelmä ja diagnostinen mittauslaite
NO20034437L (no) Gangliosid-assosierte rekombinante antistoffer og anvendelse derav ved diagnostikk og behandling av tumorer
DE60218695D1 (de) Biosensoren und messverfahren
DE60030756D1 (de) Körperflüssigkeitsmessinstrument und körperflüssigkeitsprobeentnahmegerät
AU4941101A (en) Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
AU6502199A (en) Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EP1229330A4 (en) PROTEIN-PROTEIN INTERACTIONS AND PROCESS FOR PROCESSING THIS
NO20032391D0 (no) Ekspresjonsanalyse av KIAA-nukleinsyrer og polypeptider anvendelige i diagnose og behandling av prostatakreft
NO20032393L (no) Ekspresjonsanalyse av inhibitor av differensiering av nukleinsyrer og polypeptider anvendelige i diagnose og behandling av prostatakreft
NO20020207L (no) Biologiske materialer og fremgangsmåter som er nyttige ved diagnostisering og behandling av sykdom
NO20032394L (no) Ekspresjonsanalyse av SMARC-nukleinsyrer og polypeptider anvendelige i diagnose og behandling av prostatakreft
FI981428A0 (fi) Referenssiaine käytettäväksi levosimendaanierien analyysissä
DE50108075D1 (de) Anordnung zur visuellen und quantitativen 3-D-Untersuchung von Proben
ITNA20000012V0 (it) Macchina di analisi corporea utilizzante misurazione impedenziometrica e ultrasonica.
GB9917491D0 (en) Biological materials and methods useful in the diagnosis and treastment of diseases
ZA200301143B (en) Biological materials and methods useful in the diagnosis and treatment of diseases.
GB9906217D0 (en) Biological materials and methods useful in the diagnosis and treatment of diseases
GB9917878D0 (en) Biological materials and methods useful in the diagnosis and treatment of diseases
IT1304184B1 (it) Sequenze che inducono/stimolano il reinizio della traduzione e lorouso.
SE0004261D0 (sv) Undersöknings- och behandlingsbänk
GB0113011D0 (en) Biological materials and methods useful in the diagnosis and treatment of diseases